Skip to main content

Table 1 Summary of CVOTs evaluating the cardioranal effects of GLP-1RAs in T2DM

From: GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs

Trial/year of Publication Study drug/mean follow up (years) Participants (n) Age mean (years) Male sex (n, %) Participants with established CV disease (n, %) History of heart failure (n, %) eGFR < 60 ml/min per 1.73 m2 (n, %)
ELIXA Lixisenatide 6068 60.3 3174 (69.3%) 6068 (100%) 1922 (20.3%) 1407 (23.2%)
2015 2.1 year       
LEADER Liraglutide 9340 64.3 6003 (64.3%) 6764 (72.4%) 1667 (17.8%) 2158 (23.1%)
2016 3.8 year       
SUSTAIN-6 Semaglutide 3297 64.6 2002 (60.7%) 2735 (83%) 777 (23.6%) 939 (28.5%)
2016 3.1 year       
EXSCEL Eenatide OW 14,752 62.0 9149 (62%) 10,792 (73.1%) 2389 (16.2%) 3191 (21.6%)
2017 3.2 year       
HARMONY Albiglutide 9463 64.1 6569 (69.4%) 9463 (100%) 1922 (20.3%) NR
2018 1.6 year       
REWIND Dulaglutide 9901 66.2 5312 (53.7%) 3109 (31.4%) 853 (8.6%) 2199 (22.2%)
2019 5.4 year       
PIONEER 6 Semaglutide 3183 66.0 2176 (68.4%) 2695 (84.7%) 388 (12.2%) 856 (26.8%)
2019 1.3 year       
AMPLITUDE-O Efpeglenatide 4076 64.5 2732 (67%) 3650 (89.6%) 737 (18.1%) 1287 (31.6%)
2021 1.8 year